A multicultural group practicing yoga together in a bright studio

Pallas Health vs Sprout Health: GLP-1 Comparison 2026

Pallas Health vs Sprout Health: pricing, medication type, clinical support, and which mid-market GLP-1 patient each program fits. Both programs’ prices verified August 2026 or later; each price carries its own date in the table below.

By RangeYourselfUpdated August 30, 20264 min read

Quick answer

Pallas Health and Sprout Health both offer GLP-1 telehealth, but they package medication, support, and pricing differently. The right choice depends on whether you weight cost, clinical touch, or formulation flexibility highest.

Side-by-side comparison

Feature	Pallas Health	Sprout Health
Best for	A dose-flat compounded price with provider care included and unusually detailed pharmacy and prescriber disclosure	Balance of price and clinical support
Medication type	Compounded semaglutide and tirzepatide (503A/503B partner pharmacies, six named); brand-name Wegovy, Ozempic, Mounjaro, Zepbound also offered cash-pay (never ranked or routed by RY, see editorialGuard)	Compounded semaglutide and tirzepatide; brand-name Wegovy/Zepbound listed cash-pay
Pricing model	First month intro, then 12-week prepay ($597 sema / $897 tirz per 12 weeks); one flat price at every dose; no membership fee	Public 'starting at' monthly pricing on the homepage; higher doses/formats confirmed in the signup funnel
Semaglutide price	Compounded, $199/mo average on the 12-week prepay plan ($597 every 12 weeks) after a $139 first month, verified 2026-08-30 on pallashealth.co. Same price at every dose.	From $149/mo, advertised 'starting at' (compounded semaglutide, entry dose; homepage-verified 2026-08-21); personalized rate confirmed in the signup funnel
Tirzepatide price	Compounded, $299/mo average on the 12-week prepay plan ($897 every 12 weeks) after a $179 first month, verified 2026-08-30 on pallashealth.co. Same price at every dose.	From $199/mo, advertised 'starting at' (compounded tirzepatide, entry dose; homepage-verified 2026-08-21); personalized rate confirmed in the signup funnel
Key watchout	The $199/mo figure is a 12-week prepay average ($597 billed every 12 weeks after the $139 first month), not a month-to-month rate. The platform launched in July 2026, so its standing price has no operating history yet; confirm plan term and renewal price at checkout. Its brand-name cash-pay prices run far above the manufacturers' own direct-pay programs.	The $149 (semaglutide) / $199 (tirzepatide) figures are Sprout's advertised homepage 'starting at' entry-dose prices, verified on the homepage 2026-07-16. The signup funnel personalizes the final rate; higher doses and brand-name options (Wegovy ~$1,799/mo, Zepbound ~$1,999/mo) cost more, confirm your dose's rate at enrollment
Price checked	Checked by a person August 30, 2026 · an automated check re-read it September 14, 2026	Checked by a person August 21, 2026 · an automated check re-read it September 14, 2026

When to choose Pallas Health

You want the same compounded price at every dose as you escalate
You want the pharmacy network and prescribers disclosed by name (six pharmacies named; prescriber NPIs posted)
You want provider care included in one price with no separate membership fee
You're comfortable with a 12-week prepay billing cycle

Check current Pallas Health pricing →

When to choose Sprout Health

You want one of the lowest bundled compounded entry prices with clinician access
You're looking for compounded GLP-1 without a stripped-down service tier
You're comfortable confirming the recurring price in the signup funnel before committing
You may want to escalate dose with the same provider over time

Check current Sprout Health pricing →

Full reviews

Frequently asked questions

Is Pallas Health cheaper than Sprout Health?

Sprout Health starts lower on semaglutide (From $149/mo, advertised 'starting at' (compounded semaglutide, entry dose; homepage-verified 2026-08-21); personalized rate confirmed in the signup funnel). Sprout Health starts lower on tirzepatide (From $199/mo, advertised 'starting at' (compounded tirzepatide, entry dose; homepage-verified 2026-08-21); personalized rate confirmed in the signup funnel). Higher doses can shift the picture, so confirm pricing at the dose you're likely to use long-term.

Which is better for semaglutide or tirzepatide, Pallas Health or Sprout Health?

Sprout Health starts lower on both semaglutide and tirzepatide based on listed entry pricing. That said, the right pick is the program whose support model and formulation match what you actually need.

Are Pallas Health and Sprout Health compounded or brand-name?

Pallas Health offers compounded semaglutide and tirzepatide (503a/503b partner pharmacies, six named); brand-name wegovy, ozempic, mounjaro, zepbound also offered cash-pay (never ranked or routed by ry, see editorialguard). Sprout Health offers compounded semaglutide and tirzepatide; brand-name wegovy/zepbound listed cash-pay. If you specifically want brand-name Wegovy or Zepbound, lean toward whichever explicitly supports brand access; if compounded is fine, both can typically meet that need.

Can I switch from Pallas Health to Sprout Health?

Yes, switching between Pallas Health and Sprout Health is straightforward in most states. You typically finish your current month, complete a new intake with the other provider, and they handle the prescription. Watch for overlap on auto-renewal billing and confirm any dose-tier or formulation differences with the new clinician before your next shipment.

Compare Pallas Health and Sprout Health to other programs

Alert me when this gets cheaper

These prices move. Get one email when we publish a verified price drop, the programs on this list included. No spam. Unsubscribe any time.

Related guides

About compounded GLP-1 medicationsCompounded semaglutide and tirzepatide are not FDA-approved finished products. They are prepared by state-licensed 503A pharmacies or 503B outsourcing facilities and are not individually reviewed by the FDA for safety, effectiveness, or quality. Compounders describe these preparations as using the same active ingredient as the approved medicines; the FDA has warned that some compounded products use salt forms, semaglutide sodium or semaglutide acetate, that it considers different active ingredients from the approved drug, and has issued warning letters over marketing that presents a compounded preparation as interchangeable with an approved one. The FDA declared the semaglutide shortage resolved on February 21, 2025 and the tirzepatide shortage resolved in December 2024, so the shortage-era pathway for broad compounding of these drugs has ended. Compounding now proceeds under the ordinary rules: a 503A pharmacy compounding for an individual patient on a prescription, or a 503B outsourcing facility, which compounds in bulk under CGMP and FDA registration rather than per patient. Those rules generally do not cover a product that is “essentially a copy” of an approved drug unless a prescriber documents a change that makes a significant difference for an individual patient. Talk to a clinician about contraindications including personal or family history of medullary thyroid carcinoma or MEN 2. RangeYourself does not provide medical advice, does not guarantee a prescription, and does not guarantee weight-loss results.

RangeYourself is reader-supported. We may earn a commission when you click on certain links, at no extra cost to you. Editorial recommendations are made independently. Pricing reflects publicly listed entry tiers, verified on the dates shown in the table above, and may change. Numbers like Compounded, $199/mo average on the 12-week prepay plan ($597 every 12 weeks) after a $139 first month, verified 2026-08-30 on pallashealth.co. Same price at every dose. and $149/mo, advertised 'starting at' (compounded semaglutide, entry dose; homepage-verified 2026-08-21); personalized rate confirmed in the signup funnel are starting tiers, not your guaranteed long-term cost.